4502.T in “China Becomes Pharma's Global R&D Engine”
Takeda Pharmaceutical Company Limited
Takeda has successfully sourced Chinese-developed medicines through its global rights to HUTCHMED's fruquintinib and its option agreement for Ascentage's olverembatinib.
4502.T impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 4502.T’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 4502.T impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 246 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Takeda has successfully sourced Chinese-developed medicines through its global rights to HUTCHMED's fruquintinib and its option agreement for Ascentage's olverembatinib.
Read the full China Becomes Pharma's Global R&D Engine storyBull side
1 story- Viewing
4502.T in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Takeda has successfully sourced Chinese-developed medicines through its global rights to HUTCHMED's fruquintinib and its option agreement for Ascentage's olverembatinib.
Bear side
2 stories- America Imports the World's Drug Prices
4502.T in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Takeda derives substantial revenue from globally sold specialty drugs and would face reduced lifetime product value from tighter cross-market price linkage.
- The Patent Cliff Sparks a Biotech Land Grab
4502.T in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Takeda must manage exclusivity losses and debt while finding enough new products to sustain its global revenue base.